Zhong S, Wu B, Dubois F, et al. Genomic landscape and immunological profile of glioblastoma in East Asian patients. Cell reports. Medicine. 2025;6(8):102217. doi:10.1016/j.xcrm.2025.102217
Cancer Program
Guo JA, Gong D, Evans K, et al. Integrative genomic identification of therapeutic targets for pancreatic cancer. Cell reports. 2025;44(9):116191. doi:10.1016/j.celrep.2025.116191
Chen XD, Chen Z, Wythes G, et al. Helicase-assisted continuous editing for programmable mutagenesis of endogenous genomes. Science (New York, N.Y.). 2024;386(6718):eadn5876. doi:10.1126/science.adn5876
Loi S, Settleman J, Joyce JA, et al. The next big questions in cancer research. Cell. 2023;186(8):1523-1527. doi:10.1016/j.cell.2023.01.037
Sun Y, Revach OY, Anderson S, et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023. doi:10.1038/s41586-023-05704-6
Dubrot J, Du PP, Lane-Reticker SK, et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022;23(10):1495-1506. doi:10.1038/s41590-022-01315-x
Bondeson DP, Paolella BR, Asfaw A, et al. Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nat Cancer. 2022. doi:10.1038/s43018-022-00360-7
Khadka P, Reitman ZJ, Lu S, et al. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nat Commun. 2022;13(1):604. doi:10.1038/s41467-022-28198-8
Ouspenskaia T, Law T, Clauser KR, et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol. 2022;40(2):209-217. doi:10.1038/s41587-021-01021-3
Lin S, Larrue C, Scheidegger NK, et al. An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discov. 2022;12(2):432-449. doi:10.1158/2159-8290.CD-20-1851